InnoMedica

InnoMedica is developing advanced nanotechnology-based drug delivery systems using proprietary liposomal formulations to improve drug delivery and reduce side effects.

Headquarters
InnoMedica Holding AG
Gesellschaftsstrasse 16
3012 Bern
Switzerland

Phone / Contact

T: +41 31 311 04 27
E: [email protected]

Connect

InnoMedica is a Swiss biopharmaceutical company focused on developing advanced drug delivery systems using nanotechnology. Its pipeline targets oncology and neurodegenerative diseases, utilising proprietary liposomal formulations to improve drug delivery and reduce side effects. Key developments include Talidox, a liposomal doxorubicin for targeted cancer therapy, and Tacurec, aimed at treating neurodegenerative conditions.

InnoMedica is privately owned and has approximately 50 employees.

Authors and Contacts

Pascal Halbherr
Head of Manufacturing

Article

Pascal Halbherr

Interview: Pharmapack Start-up Spotlight: InnoMedica Accelerating Trials with Novel Nanoparticle Filling

Pascal Halbherr discusses the InnoMedica's innovative nanocarrier filling technology platform, its impact on biotech and drug delivery, and the company’s bold vision for the future. InnoMedica, a Swiss biotech, is one of the 28 early-stage companies presenting cutting-edge innovations in Pharmapack Europe 2025’s Start-up Market.

Top